tetano
Editor, Senior Moderator
Antiviral Res. 2014 Aug 8. pii: S0166-3542(14)00209-5. doi: 10.1016/j.antiviral.2014.07.010. [Epub ahead of print]
Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus (H5N1) by Low Dose Natural Human IFN-α Administered to the Buccal Mucosa.
Strayer DR1, Carter WA1, Stouch BC2, Stittelaar KJ3, Thoolen RJ4, Osterhaus AD3, Mitchell WM5.
Author information
Abstract
Using an established nonhuman primate model for H5N1 highly pathogenic influenza virus infection in humans, we have been able to demonstrate the prophylactic mitigation of the pulmonary damage characteristic of human fatal cases from primary influenza virus pneumonia with a low dose oral formulation of a commercially available parenteral natural human interferon alpha (Alferon N Injection?). At the highest oral dose (62.5 IU/kg body weight) used there was a marked reduction in the alveolar inflammatory response with minor evidence of alveolar interstitial edema in contrast to the hemorrhage and inflammatory response observed in the alveoli of control animals. The mitigation of severe damage to the lower pulmonary airway was observed without a parallel reduction in viral titers. Clinical trial data will be necessary to establish its prophylactic human efficacy for highly pathogenic influenza viruses.
Copyright ? 2014. Published by Elsevier B.V.
KEYWORDS:
H5N1; Highly pathogenic; Influenza virus; Interferon; Oro-mucosal (buccal) administration
PMID:
25111905
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25111905
Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus (H5N1) by Low Dose Natural Human IFN-α Administered to the Buccal Mucosa.
Strayer DR1, Carter WA1, Stouch BC2, Stittelaar KJ3, Thoolen RJ4, Osterhaus AD3, Mitchell WM5.
Author information
Abstract
Using an established nonhuman primate model for H5N1 highly pathogenic influenza virus infection in humans, we have been able to demonstrate the prophylactic mitigation of the pulmonary damage characteristic of human fatal cases from primary influenza virus pneumonia with a low dose oral formulation of a commercially available parenteral natural human interferon alpha (Alferon N Injection?). At the highest oral dose (62.5 IU/kg body weight) used there was a marked reduction in the alveolar inflammatory response with minor evidence of alveolar interstitial edema in contrast to the hemorrhage and inflammatory response observed in the alveoli of control animals. The mitigation of severe damage to the lower pulmonary airway was observed without a parallel reduction in viral titers. Clinical trial data will be necessary to establish its prophylactic human efficacy for highly pathogenic influenza viruses.
Copyright ? 2014. Published by Elsevier B.V.
KEYWORDS:
H5N1; Highly pathogenic; Influenza virus; Interferon; Oro-mucosal (buccal) administration
PMID:
25111905
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25111905